Computational and biological sciences will likely meet on a financial equivalent to commercial software applications at the intersection of epigenetics and phar

Computational and biological sciences will likely meet on a financial equivalent to commercial software applications at the intersection of epigenetics and pharmaceuticals in the new few decades. When scientists begin to discover feasible methods to cure or manage previously incurable diseases (a more recent example of this has been attempts to cure Cystic Fibrosis), or more specifically reversing some of the diseases that our older baby boomer populations are suffering from via epigenetic methods, you can bet your bottoms that there will be a huge influx of capital in the sector and a subsequent increase in demand for computational biologists. Of course we could end up in a sort of quasi-understanding parallel to that of quantum mechanics and end up in a epigenetic limbo, but the general feeling is that of high hopes.